SCHEMBL1662709

SCHEMBL1662709

O=C(O)N1CCC(c2nc(C3CCOCC3)cn2CCOC2CCCCO2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 3/20 0.38
AKT1 P31749 3/20 0.38
PRKCB P05771 1/20 0.38
RPS6KA1 Q15418 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PLK1 P53350 1/20 0.34
KDM4C Q9H3R0 1/20 0.33
BRD4 O60885 2/20 0.33
TAF1 P21675 1/20 0.33
BRD2 P25440 1/20 0.33
BRPF1 P55201 1/20 0.33
EP300 Q09472 1/20 0.33
BRD3 Q15059 1/20 0.33
BRDT Q58F21 1/20 0.33
CREBBP Q92793 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
BRD9 Q9H8M2 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33
BAZ2A Q9UIF9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894087 0.95 MEN1 (0.39) RPS6KB1AKT1PRKCBRPS6KA1MEN1
SCHEMBL9894499 0.89 PRKCB (0.39) RPS6KB1AKT1PRKCBRPS6KA1MEN1
SCHEMBL1662694 0.85 MEN1 (0.39) MEN1KMT2APLK1KDM4CBRD4
SCHEMBL16457583 0.84 KDM4E (0.39) RPS6KB1AKT1MEN1KMT2AL3MBTL1
SCHEMBL9927820 0.84 GPR119 (0.40) MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL1662890 0.83 MEN1 (0.37) MEN1KMT2APLK1KDM4CBRD4
SCHEMBL9894818 0.82 RPS6KB1 (0.41) RPS6KB1AKT1PRKCBRPS6KA1CNR2
SCHEMBL1662935 0.81 RPS6KB1 (0.53) RPS6KB1AKT1PRKCBRPS6KA1CNR2
SCHEMBL1662360 0.81 RPS6KB1 (0.39) RPS6KB1AKT1PRKCBRPS6KA1BRD4
SCHEMBL1664790 0.76 MEN1 (0.39) MEN1KMT2APLK1KDM4CBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2491032-B1 AKT INHIBITORS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8436002-B2 AKT inhibitors ELI LILLY AND COMPANY (US) 2013-05-07 US disclosed
EP-2491032-A1 AKT INHIBITORS Eli Lilly and Company (US) 2012-08-29 EP disclosed
US-20120149684-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2012-06-14 US disclosed
WO-2011050016-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2011-04-28 WO disclosed
WO-2011050016-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149684-A1 AKT INHIBITORS AKT2, PIK3CA, AKT3 RPS6KB1 41/4885AKT1 4/4885PRKCB 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.